Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer

被引：9
|
作者：
Piotrowska, Zofia [1 ,2 ]
Drapkin, Benjamin [1 ]
Engelman, Jeffrey A. [1 ,2 ]
Nagy, Rebecca J. [3 ]
Lanman, Richard B. [3 ]
Sequist, Lecia V. [1 ,2 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Yawkey 7B, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA USA
[3] Guardant Hlth Inc, Redwood City, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 08期
关键词：
D O I：
10.1016/j.jtho.2016.03.020
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E95 / E97
页数：5
相关论文
共 50 条
  • [1] Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer
    Ichihara, Eiki
    Lovly, Christine M.
    CANCER DISCOVERY, 2015, 5 (07) : 694 - 696
  • [2] Clinical Likelihood of Sporadic Primary EGFR T790M Mutation in EGFR-Mutant Lung Cancer
    Lee, Youngjoo
    Lee, Geon Kook
    Hwang, Jung-Ah
    Yun, Tak
    Kim, Heung Tae
    Lee, Jin Soo
    CLINICAL LUNG CANCER, 2015, 16 (01) : 46 - 50
  • [3] Does T790M Disappear? Successful Gefitinib Rechallenge After T790M Disappearance in a Patient With EGFR-Mutant Non-Small-Cell Lung Cancer
    Hata, Akito
    Katakami, Nobuyuki
    Kaji, Reiko
    Fujita, Shiro
    Imai, Yukihiro
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : E27 - E29
  • [4] Safety and Efficacy of Osimertinib in Treating an EGFR-Mutant Lung Cancer Patient with a Germline EGFR T790M Mutation
    Ma, W.
    Gong, J.
    Shan, J.
    Lewis, D.
    Xiao, W.
    Hung, J.
    Moore, E. H.
    Zhang, Y.
    Mans, N. Z.
    Welborn, J.
    Lam, K. S.
    Li, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1863 - S1864
  • [5] Spatiotemporal T790M Heterogeneity in a Patient with EGFR-Mutant Non-Small-Cell Lung Cancer
    Hata, Akito
    Masago, Katsuhiro
    Katakami, Nobuyuki
    Imai, Yukihiro
    Yatabe, Yasushi
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (08) : E64 - E65
  • [6] The different path of T790M-positive EGFR-mutant lung cancer
    Yoon, Shinkyo
    Choi, Chang Min
    Lee, Jae Cheol
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [7] Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
    Su, Kang-Yi
    Tseng, Jeng-Sen
    Liao, Keng-Mao
    Yang, Tsung-Ying
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Yang, Pan-Chyr
    Yu, Sung-Liang
    Chang, Gee-Chen
    PLOS ONE, 2018, 13 (11):
  • [8] Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer
    Piotrowska, Zofia
    Hazar-Rethinam, Mehlika
    Rizzo, Coleen
    Nadres, Brandon
    Van Seventer, Emily E.
    Shahzade, Heather A.
    Lennes, Inga T.
    Iafrate, Anthony J.
    Dias-Santagata, Dora
    Leshchiner, Ignaty
    Jessop, Nicholas A.
    Hu, Haichuan
    Digumarthy, Subba R.
    Nagy, Rebecca J.
    Lanman, Richard B.
    Moody, Susan
    Niederst, Matthew J.
    Engelman, Jeffrey A.
    Hata, Aaron N.
    Corcoran, Ryan B.
    Sequist, Lecia, V
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 15
  • [9] Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
    Remon, Jordi
    Caramella, Caroline
    Joelet, Cecile
    Lacroix, Ludovic
    Lawson, Andrew
    Smalley, Sarah
    Howarth, Karen
    Gale, Davina
    Rosenfeld, Nitzan
    Green, Emma
    Plagnol, Vincent
    Planchard, David
    Bluthgen, Maria
    Gazzah, Annas
    Pannet, Chloe
    Nicotra, Claudio
    Soria, Jean-Charles
    Besse, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1255
  • [10] Monitoring of EGFR Mutations During Osimertinib Treatment in Advance EGFR-Mutant T790M Positive NSCLC
    Mohorcic, K.
    Janzic, A.
    Janzic, U.
    Rot, M.
    Kern, I.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S557 - S558
12345